SciBase Achieves Remarkable Success with Over 400,000 Nevisense Tests Sold Worldwide

SciBase Celebrates Major Milestone in Skin Health Diagnostics

SciBase Holding AB, a leading innovator in AI-based diagnostic solutions for skin disorders, has recently announced an impressive landmark with the sale of over 400,000 Nevisense tests globally. This accomplishment marks a significant step forward in the fight against skin diseases, particularly melanoma, which is a pressing health concern worldwide.

Nevisense: Pioneering Pain-Free Diagnosis for Skin Disorders

Nevisense is renowned for being the only FDA-approved and CE-marked non-invasive diagnostic technology specifically designed for dermatologists. It provides a critical evaluation of suspicious moles while assessing a patient's personalized risk for melanoma. Utilizing advanced technology, Nevisense enhances the accuracy of dermatological assessments, enabling better clinical decision-making at the point of care. This innovation supports healthcare professionals in making informed choices for early detection and intervention, subsequently improving patient outcomes.

The significance of Nevisense extends beyond melanoma; as recently highlighted in a clinical study published at the end of 2025, it can predict the development of atopic dermatitis in newborns. This revelation opens doors to new research opportunities and assures parents about proactive skin health management from infancy.

Collaborative Efforts to Expand Dermatological Solutions

In 2025, SciBase entered a pivotal partnership with Castle Biosciences, aimed at enhancing Nevisense's applicability in diagnosing various dermatological conditions. This collaboration is anticipated to yield fresh insights and strategies for addressing skin disorders, assuring that both companies are dedicated to enriching the healthcare landscape through innovative technology.

As stated by Pia Renaudin, CEO of SciBase, “With each Nevisense test, we empower clinicians to make more informed and precise decisions regarding early detection, ultimately improving patient outcomes.” This ethos reflects the core mission of SciBase: to minimize patient suffering while enhancing the quality of life through timely healthcare interventions.

Commitment to Continuous Innovation

Built on over two decades of groundbreaking research at the Karolinska Institute in Stockholm, SciBase stands at the forefront of dermatological advancements. The company is publically traded on the Nasdaq First North Growth Market since June 2, 2015, indicating strong market confidence in its vision and strategies.

SciBase’s commitment to refining its diagnostic technology aims not only to reduce healthcare costs but to increase the overall success rates of treatments provided to patients. The company is strategically poised for future growth, with an expanded focus on creating accurate, proactive solutions that address a range of skin disorders.

In conclusion, the remarkable achievement of selling over 400,000 Nevisense tests is just the beginning for SciBase. As the field of dermatology continues to evolve, so too will the innovative solutions that SciBase is dedicated to developing, ensuring that skin health remains a priority for clinicians and patients alike. For more information, you can explore their official website at www.scibase.com or refer to their investor relations portal for financial reports and press releases.